Biomarkers in diagnostic obstetric and gynecologic pathology: A review

被引:45
作者
Nucci, MR
Castrillon, DH
Bai, HW
Quade, BJ
Ince, TA
Genest, DR
Lee, KR
Mutter, GL
Crum, CP
机构
[1] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
immunohistochemistry; biomarkers; uterine neoplasms; cervix neoplasms; vulvar neoplasms;
D O I
10.1097/00125480-200303000-00001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Until recently. the histologic diagnosis of obstetrical and gynecologic neoplasia was based principally on morphologic criteria. However. interobserver reproducibility for entities such as squamous intraepithelial, endometrial, and trophoblastic disease varies widely between observers. This inherent variability in interpretation between individuals has led to wide ranges in diagnostic precision between practices, and in many cases, between recognized experts. The advent of immunohistochemistry, and the more recent accelerated discovery of new genes and their functions has resulted in the discovery of cellular proteins or nucleic acids that are differentially expressed in tumors. When applied in conjunction with existing histologic criteria, these "biomarkers" have the potential to enhance diagnostic consistency and reproducibility. The gains expected are to practicing diagnostic pathologists (who Will enjoy greater diagnostic consistency) and to academics (for whom biomarkers may uncover new pathways unappreciated by histologic diagnosis alone). However, fundamental to the success in both arenas will be critical analysis of the potential pitfalls in immunohistochemistry, strict validation of new markers as they arrive in the field, and a realistic view of their value in the laboratory management of obstetrical and gynecologic diseases.
引用
收藏
页码:55 / 68
页数:14
相关论文
共 86 条
[1]   Immunohistochemical distinction of endometrial stromal sarcoma and cellular leiomyoma [J].
Agoff, SN ;
Grieco, VS ;
Garcia, R ;
Gown, AM .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2001, 9 (02) :164-169
[2]   Gatekeeper for endometrium: the PTEN tumor suppressor gene [J].
Ali, IU .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) :861-863
[3]  
AMBROS RA, 1991, MODERN PATHOL, V4, P586
[4]   ARCHITECTURAL AND NUCLEAR MORPHOMETRICAL FEATURES TOGETHER ARE MORE IMPORTANT PROGNOSTICATORS IN ENDOMETRIAL HYPERPLASIAS THAN NUCLEAR MORPHOMETRICAL FEATURES ALONE [J].
BAAK, JPA ;
NAUTA, JJP ;
WISSEBREKELMANS, ECM ;
BEZEMER, PD .
JOURNAL OF PATHOLOGY, 1988, 154 (04) :335-341
[5]  
Benda J A, 1996, J Natl Cancer Inst Monogr, P27
[6]   Distinction between endometrial and endocervical adenocarcinoma: An immunohistochemical study [J].
Castrillon, DH ;
Lee, KR ;
Nucci, MR .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2002, 21 (01) :4-10
[7]   Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2 [J].
Castrillon, DH ;
Sun, DQ ;
Weremowicz, S ;
Fisher, RA ;
Crum, CP ;
Genest, DR .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (10) :1225-1230
[8]  
Chilosi, 1998, Adv Clin Path, V2, P15
[9]   Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms - Frequent expression in renal cell carcinoma and endometrial stromal sarcoma [J].
Chu, PG ;
Arber, DA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (03) :374-382
[10]   Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: An immunohistochemical comparison of 34 cases [J].
Chu, PG ;
Arber, DA ;
Weiss, LM ;
Chang, KL .
MODERN PATHOLOGY, 2001, 14 (05) :465-471